CJC-1295, a long-acting GHRH analog, normalized growth hormone secretion in GH-deficient rats with once-daily dosing, demonstrating sustained GH-axis restoration that could simplify GH deficiency treatment.
Key findingCJC-1295 (long-acting GHRH analog with extended half-life through DPP-IV resistance) normalized pulsatile GH secretion and IGF-1 in GH-deficient rats
What the researchers found
CJC-1295 (long-acting GHRH analog with extended half-life through DPP-IV resistance) normalized pulsatile GH secretion and IGF-1 in GH-deficient rats with once-daily SC administration — practical sustained GH-axis restoration for potential clinical simplification.
Why it matters
Relevant for cjc-1295, hormone-optimization.
How the study worked
animal-study study on cjc-1295, hormone-optimization.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2006.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
American journal of physiology. Endocrinology and metabolism, 291(6), E1290-4
Citation
Alba, Maria; Fintini, Danilo; Sagazio, Alessia; Lawrence, Betty; Castaigne, Jean-Paul; Frohman, Lawrence A; Salvatori, Roberto. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.. American journal of physiology. Endocrinology and metabolism, 291(6), E1290-4.